Abstract:Zhongqi Sun, 1 Xin Li, 1 Hongwei Liang, 1 Zhongxing Shi, 2 Hongjia Ren 3 1 Department of Radiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, People's Republic of China; 2 Department of Interventional Radiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, People's Republic of China; 3 School of Information Science and Engineering, Yanshan University, Qinhuangdao, 066004, People's Republic of China Correspondence: Zhongqi Sun, Email ; Hongjia Ren, Email Background: To develop and validate an overall survival (OS) prediction model for transarterial chemoembolization (TACE). Methods: In this retrospective study, 301 patients with hepatocellular carcinoma (HCC) who received TACE from 2012 to 2015 were collected. The residual network was used to extract prognostic information from CT images, which was then combined with the clinical factors adjusted by COX regression to predict survival using a modified deep learning model (DLOP Combin ). The DLOP Combin model was compared with the residual network model (DLOP CTR ), multiple COX regression model (DLOP Cox ), Radiomic model (Radiomic), and clinical model. Results: In the validation cohort, DLOP Combin shows the highest TD AUC of all cohorts, which compared with Radiomic (TD AUC: 0.96vs 0.63) and clinical model (TD AUC: 0.96 vs 0.62) model. DLOP Combin showed significant difference in C index compared with DLOP CTR and DLOP Cox models ( P < 0.05). Moreover, the DLOP Combin showed good calibration and overall net benefit. Patients with DLOP Combin model score ≤ 0.902 had better OS (33 months vs 15.5 months, P < 0.0001). Conclusion: The deep learning model can effectively predict the patients' overall survival of TACE. Keywords: deep learning, transarterial chemoembolization, hepatocellular carcinoma Liver cancer is the third leading cause of cancer-related deaths worldwide. 1,2 Hepatocellular carcinoma (HCC) is the most common type of liver cancer. 3 Patients with early HCC are therapeutic with transplantation, resection, and ablation, and have an overall 5-year survival rate reaching 70–80%. 4 However, approximately 80% of patients are in the Barcelona Clinic Liver Cancer staging classification B (BCLC B) at the time of diagnosis, with significantly decreased survival. 5 Currently, transcatheter arterial chemoembolization (TACE) is the first-line therapy for patients in BCLC B stage. 6 Nevertheless, the objective response rate for TACE was 52.5% and the 3-year overall survival (OS) was 40.4%. 7 Accordingly, understanding the prognosis of TACE patients and predicting the survival period of TACE patients is crucial in the overall treatment, which can stratify the risk of diseases and help clinicians to make more personalized decisions, such as determining the follow-up time and planning the treatment programme. Previous studies have suggested several clinical factors are associated with the prognosis of TACE, including tumor size, tumor numbers, and alpha-fetoprotein (AFP) levels. 8–10 Moreover, relevant researchers have developed scoring systems that integrate various clinical information, such as the BCLC B subclassification, albumin-bilirubin (ALBI) grade, and neutrophil-to-lymphocyte ratio. 11–13 The above methods can assist clinicians in predicting survival to some extent, whereas, they implicitly assume that the relationship between predictor variables and output results is linear, which may not be a valid assumption, and few studies incorporate radiomic information. CT examination contains not only tumor size and imaging features, but also more information about the prognosis of the primary tumor. 14,15 Studies have shown that illustrates that the imaging phenotype at the macro level is closely related to the tissue phenotype at the micro level, and even closely related to molecular pathways and genetic changes. 16,17 Obviously, high-dimensional information mined from CT can be used to predict the survival of TACE patients. In recent years, image-based deep learning methods have shown promising potential for predicting survival, it constructs a model with a large number of hidden layers, automatically extract features, and find various complex nonlinear relationships between input and output after repeated correction. 18,19 Therefore, deep learning can be used to predict the survival problem of TACE based on CT images. 20 However, in these studies, the prediction model did not account for im -Abstract Truncated-

Development and Validation of Deep Learning Model for Intermediate-Stage Hepatocellular Carcinoma Survival with Transarterial Chemoembolization (Mc-Hccai 002): a Retrospective, Multicenter, Cohort Study.

Development and Validation of a Deep Learning Model for Survival Prognosis of Transcatheter Arterial Chemoembolization in Patients with Intermediate-Stage Hepatocellular Carcinoma

Deep Learning-based Risk Prediction Model for Recurrence-free Survival in Patients with Hepatocellular Carcinoma Using Multi-phase CT Image

Deep learning models for predicting the survival of patients with hepatocellular carcinoma based on a surveillance, epidemiology, and end results (SEER) database analysis

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib

CT-based multimodal deep learning for non-invasive overall survival prediction in advanced hepatocellular carcinoma patients treated with immunotherapy

Deep Learning to Develop Transcriptomic Model for Survival Prediction in TCGA Patients with Hepatocellular Carcinoma.

Deep learning model based on contrast-enhanced MRI for predicting post-surgical survival in patients with hepatocellular carcinoma

Development and Validation of a Deep Learning Model for Non–Small Cell Lung Cancer Survival

Deep Learning-Based Prediction of Post-treatment Survival in Hepatocellular Carcinoma Patients Using Pre-treatment CT Images and Clinical Data

A Deep Learning Model Combining Multimodal Factors to Predict the Overall Survival of Transarterial Chemoembolization

Pretreatment Computed Tomography-Based Machine Learning Models to Predict Outcomes in Hepatocellular Carcinoma Patients who Received Combined Treatment of Trans-Arterial Chemoembolization and Tyrosine Kinase Inhibitor

Machine Learning for Dynamic Prognostication of Patients With Hepatocellular Carcinoma Using Time-Series Data: Survival Path Versus Dynamic-DeepHit HCC Model

Development and validation of machine learning models for predicting prognosis and guiding individualized postoperative chemotherapy: A real-world study of distal cholangiocarcinoma

[Survival Analysis of Patients with Intrahepatic Cholangiocarcinoma Treated with Adjuvant Chemotherapy after Radical Resection Based on CoxPH Model and Deep Learning Algorithm].

Deep Learning-Based Prediction of Future Extrahepatic Metastasis and Macrovascular Invasion in Hepatocellular Carcinoma

Survival Prediction after Transarterial Chemoembolization for Hepatocellular Carcinoma: a Deep Multitask Survival Analysis Approach

Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma

Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors

Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging

Development of prognostic models for advanced multiple hepatocellular carcinoma based on Cox regression, deep learning and machine learning algorithms